Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/04/2010US7709445 Colloidal suspension of nanoparticles based on an amphiphilic copolymer
05/04/2010US7709444 Echinocandin pharmaceutical formulations containing micelle-forming surfactants
05/04/2010US7709259 comprises supplementing the culture medium with a prostaglandin in an amount effective to promote complete hatching of the embryo (i.e., freeing of the embryo from the zona pellucida); in vitro fertilization embryo is thereby enhanced and establishment of a viable pregnancy is facilitated
05/04/2010US7709231 Genes encoding a nystatin polyketide synthase and their manipulation and utility
05/04/2010US7709211 Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
05/04/2010US7709207 Method for identifying compounds for treatment of pain
05/04/2010US7709031 Angiogenic agents from plant extracts, gallic acid, and derivatives
05/04/2010US7709028 Particulate product comprising pantethine
05/04/2010US7709026 Synergistic mixture reducing pH, adjustment oxygen concentration containing peroxy compound and bioadhesive
05/04/2010US7709024 1-(8-{4-[3-(5-Fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one (SLV 314); coated tablet comprising compressed comprises hypromellose, microcrystalline cellulose, and lubricant; G protein coupled receptor inhibitors; solubility, stability and ease of formulation
05/04/2010US7709022 Sustained-release preparations of quinolone antibiotics and method for preparation thereof
05/04/2010US7709021 Microbial cellulose wound dressing for treating chronic wounds
05/04/2010US7709020 Implantable device comprising phosphorus-containing macrolides
05/04/2010US7709014 Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
05/04/2010US7709012 Ophthalmic compositions containing a synergistic combination of two polymers
05/04/2010US7709005 Applying to the skin a composition comprising a hydrophilic foam substrate and a hydrophilic agent capable of absorbing water and a wetting agent; polyurethanes, superabsorbent polymers; surfactants; drug delivery;antiinflammatory agents; antiswelling agents; antinociceptive agents;analgesics
05/04/2010US7708998 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
05/04/2010US7708995 Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
05/04/2010US7708989 Administering nitrosated angiotensin converting enzyme inhibitors and other nitrosated compounds for cardiovascular disorders and treatment of hypertensive agents
05/04/2010US7708988 identifying a mammalian subject having an infection with said pathogenic Clostridium bacterium resistant to antibiotic, orally administering a therapeutically-effective concentration of Bacillus coagulans bacteria; reducing gastrointestinal colonization by a pathogenic Clostridium bacterium
05/04/2010US7708986 Targeted vectors for cancer immunotherapy
05/04/2010US7708979 Thermogelling polymer blends for biomaterial applications
05/04/2010CA2514158C Enhanced production of clotting factors by cryoprecipitation
05/04/2010CA2504496C N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
05/04/2010CA2476587C Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
05/04/2010CA2463896C Injectable compositions for the controlled delivery of pharmacologically active compound
05/04/2010CA2462456C Androstane 17-beta-carboxamides as androgen receptor modulators
05/04/2010CA2461013C Composition for lessening oxidative stress
05/04/2010CA2455566C (+)-cycloolivil as antioxidant obtained from stereospermum personatum
05/04/2010CA2453609C Bridged piperidine derivatives as melanocortin receptor agonists
05/04/2010CA2448863C Increased and sustained in vivo gene expression using a nucleic acid, histone, and amphipathic compound composition
05/04/2010CA2440419C Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
05/04/2010CA2439001C Water-soluble triazole antifungal agents
05/04/2010CA2437767C Heterocyclic inhibitors of erk2 and uses thereof
05/04/2010CA2433840C Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
05/04/2010CA2431519C Topical composition and method for treating urinary stress incontinence
05/04/2010CA2427608C Condensed pyradizindione derivatives as pde inhibitors
05/04/2010CA2427385C Nutritional composition for an immune condition
05/04/2010CA2417646C Topical gel delivery system
05/04/2010CA2414200C Variolin derivatives as anti-cancer agents
05/04/2010CA2412789C Compositions for improving mental concentration
05/04/2010CA2399196C Pyrimidine compounds
05/04/2010CA2388243C Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials
05/04/2010CA2385817C Substituted pyridines and pyridazines with angiogenesis inhibiting activity
05/04/2010CA2378438C Methods for preparation of lipid-encapsulated therapeutic agents
05/04/2010CA2373856C 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of drug misuse or addictive disorders
05/04/2010CA2352484C Pressurised metered dose inhalers (mdi)
05/04/2010CA2350671C Riluzole and alpha-tocopherol combination
05/04/2010CA2347981C Process for the manufacturing of alkaline salts of substituted sulphinyl compounds and products prepared thereby
05/04/2010CA2337213C Therapeutic agent for renal failure containing 4,8-inter-m-phenylene prostaglandin i2 derivative
05/04/2010CA2320467C Cycloalkene derivatives, their production and use
05/04/2010CA2312087C Preparation comprising sterically hindered amines for the prevention and treatment of inflammation
05/04/2010CA2282439C Formulations for hydrophobic pharmaceutical agents
05/04/2010CA2223503C Transferrin receptor genes
05/04/2010CA2158134C Supplemented tissue sealant
05/04/2010CA2089376C Sugar modified oligonucleotides that detect and modulate gene expression
04/2010
04/29/2010WO2010048603A1 Materials and methods for sensitizing multidrug resistant cells
04/29/2010WO2010048599A1 Methods for treating gastrointestinal diseases
04/29/2010WO2010048593A1 Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
04/29/2010WO2010048592A1 Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
04/29/2010WO2010048573A1 Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
04/29/2010WO2010048564A1 Modulators of cystic fibrosis transmembrane conductance regulator
04/29/2010WO2010048559A2 Phenylpyrazole inhibitors of store operated calcium release
04/29/2010WO2010048526A2 Modulators of cystic fibrosis transmembrane conductance regulator
04/29/2010WO2010048499A1 Platinum acridine anti-cancer compounds and methods thereof
04/29/2010WO2010048486A1 Method of synthesizing macrolide compounds
04/29/2010WO2010048483A1 Nutritional composition to promote healthy development and growth
04/29/2010WO2010048455A1 Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
04/29/2010WO2010048452A2 Polycyclic compounds and methods related thereto
04/29/2010WO2010048446A2 Modulation of axon degeneration
04/29/2010WO2010048423A1 Levetiracetam immunoassays
04/29/2010WO2010048384A2 Arformoterol and tiotropium compositions and methods for use
04/29/2010WO2010048358A2 Ethoxyphenylmethyl inhibitors of sglt2
04/29/2010WO2010048352A2 Methods for treating eye disorders
04/29/2010WO2010048332A2 Compounds for treating ophthalmic diseases and disorders
04/29/2010WO2010048314A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
04/29/2010WO2010048302A1 Naphthamides as anticancer agents
04/29/2010WO2010048298A1 Combination therapy with peptide epoxyketones
04/29/2010WO2010048287A2 Radioprotective agents
04/29/2010WO2010048273A2 Methods and compounds for treatment of neurodegenerative disorders
04/29/2010WO2010048264A2 Methods and compositions for the treatment of immunoinflammatory disorders
04/29/2010WO2010048228A2 Compositions and methods for inhibiting expression of transthyretin
04/29/2010WO2010048207A2 Aryl gpr120 receptor agonists and uses thereof
04/29/2010WO2010048164A2 N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints
04/29/2010WO2010048149A2 Heterocyclic modulators of gpr119 for treatment of disease
04/29/2010WO2010048114A1 Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
04/29/2010WO2010048095A2 Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
04/29/2010WO2010048087A2 Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
04/29/2010WO2010048064A2 Drug delivery system and its use in the treatment of postherpetic neuralgia
04/29/2010WO2010048059A1 Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
04/29/2010WO2010048018A1 Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
04/29/2010WO2010048017A1 Disubstituted azepan orexin receptor antagonists
04/29/2010WO2010048013A1 2,5-disubstituted morpholine orexin receptor antagonists
04/29/2010WO2010048012A1 2,5-disubstituted piperidine orexin receptor antagonists
04/29/2010WO2010047990A1 Fused heterocyclic m1 receptor positive allosteric modulators
04/29/2010WO2010047982A1 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
04/29/2010WO2010047956A1 Azolopyrrolone melanin concentrating hormone receptor-1 antagonists
04/29/2010WO2010047927A1 Ophthalmic compositions useful for improving visual acuity
04/29/2010WO2010047835A2 Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
04/29/2010WO2010047831A1 Stable metronidazole gel formulations
1 ... 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 ... 7860